Panel Discussion: Packaging for the connected age EP News Bureau Apr 13, 2025 PPL Conclave 2025 | Day 2 | 8th March 2025 | Hyderabad
The use of FTWZs has risen by 20 to 25% every quarter after the pandemic Viveka Roychowdhury Apr 12, 2025 Ranjit Ray, Senior Vice President - Economic Zones and Contract Logistics, MENA and India Subcontinent, DP World discusses how…
DP World inaugurates Nhava Sheva business park FTWZ in Mumbai to strengthen India-UAE trade links EP News Bureau Apr 11, 2025 Dubai Crown Prince Sheikh Hamdan opens DP World’s new FTWZ in Mumbai, expanding logistics infrastructure and trade connectivity…
CDSCO issues compliance framework for SEZ-to-DTA drug transfers Neha Aathavale Apr 11, 2025 New circular standardises licensing pathway for domestic diversion of SEZ-manufactured drugs; however system-level changes raise…
Cipla receives US FDA approval for generic version of Abraxane EP News Bureau Apr 11, 2025 Cipla secures final USFDA approval for Protein-bound Paclitaxel 100 mg/vial; launch planned in H1 FY26 in the US market
Granules India completes acquisition of Swiss CDMO Senn Chemicals to expand peptide capabilities EP News Bureau Apr 11, 2025 The ₹192.5 crore transaction marks Granules India's entry into the CDMO segment and expands its presence in peptide-based APIs
Morepen Laboratories to expand domestic salesforce by 1,000 as part of formulations growth plan EP News Bureau Apr 11, 2025 Expansion targets ₹1,000 crore finished dosages business by 2030, aligning with India's vision for affordable and accessible…
OneSource specialty pharma secures ANVISA GMP certification for Bengaluru unit 2 facility EP News Bureau Apr 10, 2025 Approval enables OneSource to supply drug-device combinations including GLP-1s to Brazil, ahead of Semaglutide generics entering…
N-FIS was developed to address a critical challenge in healthcare—needle phobia Viveka Roychowdhury Apr 10, 2025 Integri Medical has launched a needle-free injection system (N-FIS) to address needle phobia and enhance patient convenience.In…
Axsome Therapeutics’ AXS-05 challenges current standard of care as promising non-antipsychotic for… EP News Bureau Apr 10, 2025 AXS-05 emerges as a potential first-in-class, non-antipsychotic treatment for Alzheimer’s agitation, positioning Axsome…